sildenafil ratiopharm
ratiopharm gmbh - sildenafil - disfuncion erectil - urológicos - tratamiento de hombres con disfunción eréctil, que es la incapacidad para lograr o mantener una erección peniana suficiente para el desempeño sexual satisfactorio. para que el sildenafil sea efectivo, se requiere estimulación sexual.
acido alendronico/colecalciferol ratiopharm 70 mg/5.600 ui comprimidos
teva pharma s.l.u. - alendronato sodio monohidrato; colecalciferol - comprimido - 70 mg/5.600 ui - alendronato sodio monohidrato 70 mg; colecalciferol 5600 ui - Ácido alendrónico y colecalciferol
acido alendronico/colecalciferol ratiopharm 70mg/2.800 ui comprimidos
teva pharma s.l.u. - alendronato sodio monohidrato; colecalciferol - comprimido - 70 mg/2.800 ui - alendronato sodio monohidrato 70 mg; colecalciferol 2800 ui - Ácido alendrónico y colecalciferol
metformina ratiopharm 500 mg comprimidos recubiertos con pelicula
ratiopharm españa, s.a. - metformina hidrocloruro - excipientes: n/a - fÁrmacos hipoglucemiantes excluyendo insulinas - biguanidas - metformina
metformina ratiopharm 1000 mg comprimidos recubiertos con pelicula
ratiopharm españa, s.a. - metformina hidrocloruro - excipientes: n/a - fÁrmacos hipoglucemiantes excluyendo insulinas - biguanidas - metformina
duloxetina ratiopharm 30 mg capsulas duras gastrorresistentes efg
ratiopharm espana s.a. - duloxetina hidrocloruro - cÁpsula dura gastrorresistente - 30 mg - duloxetina hidrocloruro 30 mg - duloxetina
duloxetina ratiopharm 60 mg capsulas duras gastrorresistentes efg
ratiopharm espana s.a. - duloxetina hidrocloruro - cÁpsula dura gastrorresistente - 60 mg - duloxetina hidrocloruro 60 mg + mg - duloxetina
desloratadina ratiopharm 0,5 mg/ml solucion oral efg
ratiopharm espana s.a. - desloratadina - soluciÓn oral - 0,5 mg/ml - desloratadina 0,5 mg - desloratadina
claritromicina unidia ratiopharm 500 mg comprimidos de liberacion prolongada efg
ratiopharm espana s.a. - claritromicina - comprimido de liberaciÓn prolongada - 500 mg - claritromicina 500 mg - claritromicina
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.